157 related articles for article (PubMed ID: 37474423)
1. Factors associated with lung function response with oral antibiotic treatment of pulmonary exacerbations in cystic fibrosis.
Blanchard AC; Shaw M; Ratjen F; Tullis E; Daneman N; Waters V
J Cyst Fibros; 2023 Sep; 22(5):880-883. PubMed ID: 37474423
[TBL] [Abstract][Full Text] [Related]
2. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.
Waters V; Stanojevic S; Klingel M; Chiang J; Sonneveld N; Kukkar R; Tullis E; Ratjen F
J Cyst Fibros; 2015 Nov; 14(6):770-6. PubMed ID: 26265220
[TBL] [Abstract][Full Text] [Related]
3. Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis.
Stanojevic S; McDonald A; Waters V; MacDonald S; Horton E; Tullis E; Ratjen F
Thorax; 2017 Apr; 72(4):327-332. PubMed ID: 27539619
[TBL] [Abstract][Full Text] [Related]
4. The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations.
Zikic A; Ratjen F; Shaw M; Tullis E; Waters V
J Cyst Fibros; 2022 Sep; 21(5):759-765. PubMed ID: 35650003
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
6. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.
Wagener JS; Rasouliyan L; VanDevanter DR; Pasta DJ; Regelmann WE; Morgan WJ; Konstan MW;
Pediatr Pulmonol; 2013 Jul; 48(7):666-73. PubMed ID: 22888106
[TBL] [Abstract][Full Text] [Related]
7. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
Somayaji R; Russell R; Cogen JD; Goss CH; Nick SE; Saavedra MT; Taylor-Cousar JL; Nick JA; Nichols DP
Ann Am Thorac Soc; 2019 Jul; 16(7):853-860. PubMed ID: 30840835
[No Abstract] [Full Text] [Related]
8. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V
Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447
[No Abstract] [Full Text] [Related]
9. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations.
VanDevanter DR; O'Riordan MA; Blumer JL; Konstan MW
Respir Res; 2010 Oct; 11(1):137. PubMed ID: 20925941
[TBL] [Abstract][Full Text] [Related]
10. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
[No Abstract] [Full Text] [Related]
12. A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment.
Waters V; Shaw M; Perrem L; Quon BS; Tullis E; Solomon M; Rayment JH; Lavoie A; Tse SM; Daigneault P; Bilodeau L; Price A; Nicholson M; Chin M; Parkins M; McKinney ML; Tam JS; Stanojevic S; Grasemann H; Ratjen F;
Eur Respir J; 2024 Jun; 63(6):. PubMed ID: 38697648
[TBL] [Abstract][Full Text] [Related]
13. Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.
Sagel SD; Thompson V; Chmiel JF; Montgomery GS; Nasr SZ; Perkett E; Saavedra MT; Slovis B; Anthony MM; Emmett P; Heltshe SL
Ann Am Thorac Soc; 2015 May; 12(5):708-17. PubMed ID: 25714657
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
15. Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.
Briggs EC; Nguyen T; Wall MA; MacDonald KD
Clin Respir J; 2012 Jan; 6(1):56-64. PubMed ID: 21595857
[TBL] [Abstract][Full Text] [Related]
16. Macrolide antibiotics (including azithromycin) for cystic fibrosis.
Southern KW; Solis-Moya A; Kurz D; Smith S
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD002203. PubMed ID: 38411248
[TBL] [Abstract][Full Text] [Related]
17. Glycemic control and FEV
Okoniewski W; Hughan KS; Weiner GA; Weiner DJ; Forno E
J Cyst Fibros; 2020 May; 19(3):460-465. PubMed ID: 31980357
[TBL] [Abstract][Full Text] [Related]
18. Rhinovirus-associated pulmonary exacerbations show a lack of FEV1 improvement in children with cystic fibrosis.
Cousin M; Molinari N; Foulongne V; Caimmi D; Vachier I; Abely M; Chiron R
Influenza Other Respir Viruses; 2016 Mar; 10(2):109-12. PubMed ID: 26493783
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients.
Waters VJ; Stanojevic S; Sonneveld N; Klingel M; Grasemann H; Yau YC; Tullis E; Wilcox P; Freitag A; Chilvers M; Ratjen FA
J Cyst Fibros; 2015 Nov; 14(6):755-62. PubMed ID: 25690407
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
